• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Clin Microbiol . Comparison of Antibody Class Specific SARS-CoV-2 Serology for the Diagnosis of Acute COVID-19

tetano

Editor, Senior Moderator
J Clin Microbiol


. 2021 Jan 19;JCM.02026-20.
doi: 10.1128/JCM.02026-20. Online ahead of print.
Comparison of Antibody Class Specific SARS-CoV-2 Serology for the Diagnosis of Acute COVID-19


Hans Verkerke[SUP] 1 1 [/SUP], Michael Horwath[SUP] 1 [/SUP], Bejan Saeedi[SUP] 1 [/SUP], Darra Boyer[SUP] 1 [/SUP], Jerry W Allen[SUP] 1 1 1 [/SUP], Joshua Owens[SUP] 1 [/SUP], Connie M Arthur[SUP] 1 1 [/SUP], Hirotomo Nakahara[SUP] 1 [/SUP], Jennifer Rha[SUP] 1 1 [/SUP], Kashyap Patel[SUP] 1 1 [/SUP], Shang-Chuen Wu[SUP] 1 [/SUP], Anu Paul[SUP] 1 [/SUP], Nini Yasin[SUP] 1 [/SUP], Jianmei Wang[SUP] 1 [/SUP], Sooncheon Shin[SUP] 1 [/SUP], DeAndre Brown[SUP] 1 [/SUP], Katherine Normile[SUP] 1 [/SUP], Lisa Cole[SUP] 1 [/SUP], Mark Meyers[SUP] 1 [/SUP], Heather Lin[SUP] 1 [/SUP], Emily Woods[SUP] 1 [/SUP], Jennifer Isaac[SUP] 1 [/SUP], Kari Broder[SUP] 1 [/SUP], Jenna Wade[SUP] 1 [/SUP], Robert C Kauffman[SUP] 2 [/SUP], Ravi Patel[SUP] 2 [/SUP], Cassandra D Josephson[SUP] 1 1 [/SUP], Stacian Reynolds[SUP] 1 [/SUP], Melanie Sherman[SUP] 1 [/SUP], Jens Wrammert[SUP] 2 [/SUP], David Alter[SUP] 1 [/SUP], Jeannette Guarner[SUP] 1 [/SUP], John D Roback[SUP] 1 1 [/SUP], Andrew Neish[SUP] 3 [/SUP], Sean R Stowell[SUP] 3 1 1 [/SUP]



Affiliations

Abstract

Accurate diagnosis of acute severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) infection is critical for appropriate management of patients with this disease. We examined the possible complementary role of lab developed class-specific clinical serology in assessing SARS-CoV-2 infection in hospitalized patients. Serological tests for IgG, IgA, and IgM antibodies against the receptor binding domain (RBD) of SARS-CoV-2 were evaluated using samples from real time RT PCR (qRT-PCR)-confirmed in-patient COVID-19 cases. We analyzed the influence of timing and clinical severity on the diagnostic value of class-specific coronavirus disease 2019 (COVID-19) serology testing. Cross-sectional analysis revealed a higher sensitivity and specificity at lower optical density cutoffs for IgA in hospitalized patients when compared to IgG and IgM serology (IgG area under the curve (AUC): 0.91; 95%CI 0.89 to 0.93 vs. IgA AUC: 0.97; 95% CI 0.96 to 0.98 vs. IgM AUC: 0.95; 95% CI 0.92 to 0.97). The enhanced performance of IgA serology was apparent in the first two weeks after symptom onset and the first week after PCR testing. In patients requiring intubation, all three tests exhibit enhanced sensitivity. Among PCR-negative patients under investigation for SARS-CoV-2 infection 2 out of 61 showed clear evidence of seroconversion IgG, IgA and IgM. Suspected false-positive results in the latter population were most frequently observed in IgG and IgM serology tests. Our findings suggest the potential utility of IgA serology in the acute setting and explore the benefits and limitations of class-specific serology as a complementary diagnostic tool to PCR for COVID-19 in the acute setting.
 
Back
Top Bottom